AGM Statement

RNS Number : 8391V

Evgen Pharma PLC

26 July 2018

 

For immediate release

26 July 2018

 

Evgen Pharma plc

 ("Evgen" or "the Company")

AGM Statement

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will hold its Annual General Meeting ("AGM") later today in Manchester. At the AGM, the Company's Chairman, Barry Clare, will make the following statement:

"The current financial year has seen major progress with SFX-01, our lead product candidate, which continues to progress through two Phase II trials in metastatic breast cancer and subarachnoid haemorrhage, a type of stroke.

"The final read-out from both trials continues to be expected at around the end of this calendar year, marking important value inflexion points in the clinical development of SFX-01.

"We have already announced highly encouraging data from the metastatic breast cancer trial in an interim update in June 2018, which revealed SFX-01's signs of anti-tumour activity in a patient group where other treatment options had failed.

"Furthermore, yesterday we announced that the main aims of the metastatic breast cancer trial had been achieved, namely a favourable safety profile and evidence of clinical benefit, and that recruitment into the trial had been concluded at 50 patients rather than the total of 60 allowed under the trial protocol. We await the final details of the read-out of the trial with excitement, and see the likely next step for SFX-01 in metastatic breast cancer as a placebo-controlled trial with SFX-01 in combination with second-line hormone therapy in patients who have failed on CDK4/6 inhibitors.

"Patient recruitment continues on track in the subarachnoid haemorrhage trial with all three sites recruiting, including the most recent site addition, St Bartholomew's Hospital, London.

"We look forward to providing further updates on both the clinical and corporate development of the Company during the months ahead."

Enquiries:

Evgen Pharma plc Dr Stephen Franklin, CEO Richard Moulson, CFO www.evgen.com	c/o [phone]
Buchanan Mark Court, Sophie Wills, Tilly Abraham	[phone]
Northland Capital Partners Limited Matthew Johnson, Tom Price, Gerry Beaney (Corporate Finance) Rob Rees (Corporate Broking)	[phone]

Notes for editors:

About Evgen Pharma plc

Evgen is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/ 

 

END

 

 

AGMEASXKAAPPEEF